Research
Hormonal
Leptin, amylin, and adiponectin are recommended as core biomarkers for obesity trials to assess energy homeostasis and predict treatment response.
Obesity trials should measure leptin, amylin, and adiponectin to understand energy homeostasis. Leptin reflects fat stores, amylin promotes satiation, and adiponectin is linked to insulin sensitivity and inflammation.
GoodSupportsHIGH confidence
As exemplified by leptin (recommended)... The measurement of fasting levels of the pancreatic peptide amylin is recommended... Adiponectin, particularly high-molecular-weight (HMW) adiponectin, is recommended.
Why this rating
Consensus guideline.
Source
Accumulating Data to Optimally Predict Obesity Treatment (ADOPT): Recommendations from the Biological Domain
Michael Rosenbaum et al. · Obesity · 2018
DOI 10.1002/oby.22156
clinical_guidelineCited 30×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Anthropometric measures (BMI, waist circumference, waist-to-hip ratio) are recommended as feasible, cost-effective core measures for obesity clinical trials, despite being less accurate than imaging methods like DXA or MRI.Good
- Bioelectrical Impedance Spectroscopy (BIS) is recommended as a feasible, noninvasive, and inexpensive method to assess body fat mass and visceral fat, explaining 80-90% of variance in fat mass compared to gold standards.Good
- Calculated Resting Energy Expenditure (REE) using the Mifflin-St. Jeor equation is recommended over direct calorimetry for large clinical trials due to feasibility, though direct measurement is suggested if resources allow.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →